CO6260078A2 - Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros - Google Patents

Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros

Info

Publication number
CO6260078A2
CO6260078A2 CO10019664A CO10019664A CO6260078A2 CO 6260078 A2 CO6260078 A2 CO 6260078A2 CO 10019664 A CO10019664 A CO 10019664A CO 10019664 A CO10019664 A CO 10019664A CO 6260078 A2 CO6260078 A2 CO 6260078A2
Authority
CO
Colombia
Prior art keywords
post
traumatic stress
patient
disorder
benzodiazepina
Prior art date
Application number
CO10019664A
Other languages
English (en)
Spanish (es)
Inventor
Tom Woiwode
Mark Moran
Original Assignee
Synosia Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics filed Critical Synosia Therapeutics
Publication of CO6260078A2 publication Critical patent/CO6260078A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CO10019664A 2007-07-23 2010-02-19 Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros CO6260078A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93503607P 2007-07-23 2007-07-23

Publications (1)

Publication Number Publication Date
CO6260078A2 true CO6260078A2 (es) 2011-03-22

Family

ID=40281815

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10019664A CO6260078A2 (es) 2007-07-23 2010-02-19 Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros

Country Status (12)

Country Link
US (1) US20090054403A1 (https=)
EP (1) EP2182952A4 (https=)
JP (1) JP2010534676A (https=)
CN (1) CN101951912A (https=)
AU (1) AU2008279091A1 (https=)
CA (1) CA2707858A1 (https=)
CO (1) CO6260078A2 (https=)
MX (1) MX2010000937A (https=)
NZ (1) NZ583193A (https=)
RU (1) RU2458691C2 (https=)
SG (1) SG183069A1 (https=)
WO (1) WO2009015248A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ583191A (en) * 2007-07-23 2012-06-29 Biotie Therapies Inc 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
AU2016208412A1 (en) * 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
MX2010001390A (es) * 2007-08-06 2010-08-02 Synosia Therapeutics Inc Métodos para el tratamiento de dependencia.
HRP20171739T1 (hr) * 2009-11-20 2018-03-09 Tonix Pharma Holdings Limited Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
JP6310542B2 (ja) 2013-03-15 2018-04-11 トニックス ファーマシューティカルズ， インコーポレイテッド シクロベンザプリン塩酸塩およびアミトリプチリン塩酸塩の共融製剤
CA3089881C (en) * 2013-11-26 2024-04-02 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss
SG11201701995PA (en) 2014-09-18 2017-04-27 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
RU2614697C1 (ru) * 2016-04-12 2017-03-28 Общество с ограниченной ответственностью "Нормофарм" Нейропротекторное средство
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
BR112019024845A2 (pt) * 2017-05-30 2020-06-09 G Emerson Paul composições e métodos para regular cascatas hormonais em transtornos de estresse
US11284934B2 (en) * 2017-07-05 2022-03-29 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating sleep disorders in patients via renal neuromodulation
CN111479812A (zh) 2017-12-04 2020-07-31 巴尔-波特拉及康邦亚股份有限公司 多巴胺-b-羟化酶抑制剂
US11826321B2 (en) 2017-12-11 2023-11-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN109966281B (zh) * 2019-04-11 2021-04-27 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用
US12521362B2 (en) * 2019-07-25 2026-01-13 Tokyo University Of Science Foundation Agent for treating, preventing, or improving psychiatric and nervous system disorders or symptoms
KR20250116086A (ko) * 2022-11-30 2025-07-31 블링크랩 리미티드 안검 추적을 이용한 정신약리학적 시스템 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1425017A1 (en) * 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
EP1734920A2 (en) * 2004-02-13 2006-12-27 Neuromolecular Inc. Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
CN101257907A (zh) * 2005-07-06 2008-09-03 塞普拉科公司 左旋佐匹克隆和抗抑郁剂的组合
WO2008115706A1 (en) * 2007-03-16 2008-09-25 Emory University Methods and compositions for treatment of drug addiction
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder

Also Published As

Publication number Publication date
JP2010534676A (ja) 2010-11-11
SG183069A1 (en) 2012-08-30
WO2009015248A1 (en) 2009-01-29
AU2008279091A1 (en) 2009-01-29
RU2458691C2 (ru) 2012-08-20
RU2010106014A (ru) 2011-08-27
EP2182952A4 (en) 2010-09-08
EP2182952A1 (en) 2010-05-12
MX2010000937A (es) 2010-06-25
CA2707858A1 (en) 2009-01-29
CN101951912A (zh) 2011-01-19
NZ583193A (en) 2012-05-25
US20090054403A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
CO6260078A2 (es) Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros
AR081450A1 (es) Tratamiento de sarcoidosis usando celulas madre de placenta
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
PA8778101A1 (es) Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
AR061669A1 (es) Aplicacion de alta frecuencia de terapia con toxina botulinica
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
UY33700A (es) ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?.
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
MX2022001623A (es) Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla.
MX2018011480A (es) Metodos de intervencion temprana para prevenir o aminorar toxicidad.
ECSP11011275A (es) Inhibidor de sglt2 para tratar diabetes mellitus de tipo 1, diabetes mellitus de tipo 2, alteración de la tolerancia a la glucosa e hiperglucemia.
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX2015012520A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
CO6220937A2 (es) Compuestos triciclicos composiciones y procedimientos
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BR112014009785A8 (pt) método para tratar ou reduzir efp
AR063470A1 (es) Terapia combinada
BR112014003704A2 (pt) moduladores ror gama
ECSP13012551A (es) Terapia de combinación para tratar infección por hcv.
BR112014012746A2 (pt) nanoveículos de diagnóstico e/ou terapêutica direcionada por mmp

Legal Events

Date Code Title Description
FA Application withdrawn